IQWiG Backs Novartis’ Jetrea, Drops Almirall’s Constella On Same Day
This article was originally published in The Pink Sheet Daily
Executive Summary
Germany’s IQWiG has backed Novartis’ Jetrea for VMT, albeit with restricted indication, but knocked back Almirall’s Constella, citing study irrelevance.
You may also be interested in...
Linzess Continues On Strong Launch Trajectory, Says Ironwood/Forest
Both Ironwood and its specialty pharma partner Forest Laboratories are tying their future to the gastrointestinal drug, which has been gaining traction during its first six months on the market, despite the tough environment for primary care drugs.
Novartis Triumphs At EMA With Jetrea, But Merck Has Suspension of Three Merck Products Confirmed
The EMA has given the nod to Novartis subsidiary Alcon’s vitreomacular traction drug Jetrea and agreed to an indication extension for its Ilaris product to treat gouty arthritis. EMA’s Committee for Medicinal Products for Human Use also confirmed a recommendation to suspend the marketing authorizations of three Merck Sharp & Dohme products used to treat adults with dyslipidemia.
Signifor Approval Highlights Success Of Novartis’ Parallel Development Strategy
Following its approval in Europe earlier in 2012, the FDA approval of Signifor for Cushing’s disease is just the latest piece of a strategy to bring the injectable to market in multiple indications, including acromegaly.